Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate
Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate
Cytek Biosciences 2024 年第一季度调整后每股收益 (0.05) 未达到预期 (0.04) 美元，销售额4,49亿美元超过4,358.6万美元的预期
Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $44.900 million which beat the analyst consensus estimate of $43.586 million by 3.01 percent. This is a 21.06 percent increase over sales of $37.088 million the same period last year.
Cytek Biosciences（纳斯达克股票代码：CTKB）公布的季度亏损为每股0.05美元（0.05美元），比分析师普遍预期的0.04美元（0.04美元）低25％。该公司公布的季度销售额为4,49亿美元，比分析师普遍预期的4358.6万美元高出3.01％。这比去年同期的3708.8万美元的销售额增长了21.06％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。